Adjusted competing risks regression for prostate-cancer-specific survival showed an advantage over SOC-only for SOC + Doc (subHR 0·79, 95% CI 0·65–0·96; p=0·019) and SOC + ZA + Doc (0·78, 0·65–0·95; p=0·013), but not SOC + ZA (0·95, 0·79–1·15; p=0·613). This evidence concerns the gene UBXN11 and prostate cancer.